Form 4: scPharmaceuticals Director Sara Bonstein Granted 30,000 Stock Options

scPharmaceuticals Inc. Director Sara Bonstein was granted 30,000 stock options with an exercise price of $3.85, vesting fully by June 2026 or the next annual meeting.

Summary

• Sara Bonstein, a Director of scPharmaceuticals Inc. (SCPH), was granted 30,000 stock options on June 3, 2025.
• The stock options have an exercise price of $3.85 per share.
• These options will vest in full upon the earlier of June 3, 2026, or the date of the Issuer's next annual meeting of stockholders.
• The options have an expiration date of June 3, 2035.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as it indicates standard corporate governance and incentive alignment, but it's a routine transaction with no immediate significant financial impact or new strategic direction.

Positives

• The grant of stock options to a director aligns management and board interests with shareholder value, as the options gain value if the stock price increases.
• This compensation structure is a common practice for retaining and incentivizing board members in publicly traded companies.

Future Outlook

The vesting schedule indicates that the options will fully vest by June 3, 2026, or upon the company's next annual meeting, providing a future incentive for the director.

Industry Context

This transaction is a routine compensation event for a director in the biotechnology or pharmaceutical industry, reflecting standard practices for incentivizing board members through equity grants.

Comparison to Industry Standards

• The grant of stock options to a director is a standard component of executive and board compensation across the pharmaceutical and biotech sectors, aiming to align long-term interests.
• The vesting schedule, tied to a specific date or the next annual meeting, is also a common mechanism to ensure continued engagement and performance.

Related Party Transactions

• The grant of stock options to a director is a form of related party transaction, representing compensation from the company to a member of its board.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders, as the options' value is tied to the company's stock performance. However, it also represents potential future dilution if options are exercised.
• Management/Board: Provides an incentive for the director to contribute to the company's long-term success.

Next Steps

• The stock options will vest in full upon the earlier of June 3, 2026, or the next annual meeting of scPharmaceuticals Inc. stockholders.
• The options can be exercised at $3.85 per share until their expiration on June 3, 2035.

Key Dates

Recommendation

Keywords

scPharmaceuticals, SCPH, Stock Options, Director Compensation, SEC Form 4, Beneficial Ownership, Equity Grant, Corporate Governance